Study of Atezolizumab + Bevacizumab in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma

Conditions

• Advanced Non-Clear Cell Kidney Cancer

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• Bevacizumab — DRUG
• Atezolizumab — DRUG

Study Details

This research study is studying the combination of Atezolizumab and Bevacizumab as a possible treatment for Advanced Non-Clear Cell Kidney Cancer.

Key Dates

Start date

Jul 15, 2016

Status verified

Jan 2025

Primary completion

Nov 13, 2019

Completion

Dec 31, 2024

Study Design

Enrollment

65 participants (actual)

Allocation

NA

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Arms

• Experimental: Bevacizumab And Atezolizumab Combination
  1200 mg of Atezolizumab intravenously x 3 weeks 15 mg/kg of Bevacizumab intravenously x 3 weeks. One cycle will be 3 weeks in duration.

Primary Outcome Measure

Best Overall Response Rate [ Time Frame: Measured every 6 weeks for the first 24 weeks and then every 12 weeks while on treatment. The median (range) of treatment time was 9.5 (1-42) cycles, thus participants were assessed up to ~32 months . ]

Locations (4)

Find similar trials in La Jolla, CA